Based on consultation, peptide care may support the healing of soft tissue like muscles, ligaments, and tendons
Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, et al
In the response to food intake, it stimulates the release of insulin and inhibits the release of glucagon, which is a hormone that raises our blood sugar
7 Exenatide is the most prevalent GLP-1 in clinical trials for AD and PD treatments
What the new mechanism is: GLP-1 : appetite regulation, improved glucose control GIP : incretin effects that may augment metabolic benefits Glucagon receptor activity : potentially influences energy expenditure and fat metabolism (while requiring careful balancing of tolerability and metabolic effects) What results look like (so far): Phase 2 (48 weeks) published in NEJM showed substantial mean weight reductions (with higher doses showing very large effects)
With advancing age, GH production declines, a phenomenon paralleled by physical and functional alterations similar to those observed in AGHD